Clinical Trials
42 trialsStudy of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners AG
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
AbbVie
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)
Moonlight Bio, Inc
Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas
M.D. Anderson Cancer Center
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors
National Cancer Institute (NCI)
MK-6070-001
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
IDEAYA Biosciences
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer
Ohio State University Comprehensive Cancer Center
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
KEYNOTE 158
Merck Sharp & Dohme LLC
A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET
Fox Chase Cancer Center
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase I Study of HS-20108 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
National Institutes of Health Clinical Center (CC)
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
Hoffmann-La Roche
A Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies
23andMe, Inc.
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
DUET-2
Xencor, Inc.
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies
M.D. Anderson Cancer Center
Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas
University of Maryland, Baltimore
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 2a Desipramine in Small Cell Lung Cancer and Other High-Grade Neuroendocrine Tumors
Stanford University
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
Virginia Commonwealth University
HIPPO-SPARE 01
University of Erlangen-Nürnberg Medical School
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
Yale University
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
National Cancer Institute (NCI)
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Novartis
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
National Institutes of Health Clinical Center (CC)
FR-WB-TT/che
The University of Texas Health Science Center, Houston
Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
Mannkind Corporation